Table 2

Patient disposition and baseline characteristics

MSRASLE
Placebo
(n=54)
Evobrutinib
(n=208)
Placebo
(n=97)
Evobrutinib
(n=293)
Placebo
(n=120)
Evobrutinib
(n=360)
Age (years)41.5 (±10.7)42.2 (±10.5)52.9 (±12.1)52.6 (±12.3)40.2 (±12.4)40.7 (±12.3)
Age group, n (%)
 ≤55 years48 (88.9)183 (88.0)54 (55.7)160 (54.6)108 (90.0)315 (87.5)
 ≥55 years6 (11.1)25 (12.0)43 (44.3)133 (45.4)12 (10.0)45 (12.5)
Gender, n (%)
 Female40 (74.1)144 (69.2)77 (79.4)235 (80.2)112 (93.3)339 (94.2)
 Male14 (25.9)64 (30.8)20 (20.6)58 (19.8)8 (6.7)21 (5.8)
Race, n (%)
 White54 (100.0)208 (100.0)92 (94.8)282 (96.2)66 (55.0)224 (62.2)
 Black0 (0.0)0 (0.0)1 (1.0)2 (0.7)10 (8.3)35 (9.7)
 Asian0 (0.0)0 (0.0)1 (1.0)2 (0.7)26 (21.7)59 (16.4)
 Other0 (0.0)0 (0.0)3 (3.1)7 (2.4)18 (15.0)42 (11.7)
Duration of disease (years)7.0 (±6.4)7.6 (±6.3)6.1 (±6.4)7.0 (±6.6)6.3 (±6.2)6.6 (±6.2)
Weight (kg)69.5 (±13.6)70.6 (±15.1)74.5 (±19.7)75.0 (±16.7)67.5 (±18.4)69.3 (±18.9)
  • Data are mean (±SD), unless stated otherwise.

  • MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.